NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines

References

• Hummel JL, Lichty BD, Reis M, et al. Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Leukemia 1996;10:1370–1376.
   PubMed Web of Science ®Google Scholar
• Dürig J, Ebeling P, Grabellus F, et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007;67:8653–8661.
   PubMed Web of Science ®Google Scholar
• Bertilaccio MT, Scielzo C, Simonetti G, et al. A novel Rag2-/-gammac-/--xenograft model of human CLL. Blood 2010;115:1605–1609.
   PubMed Web of Science ®Google Scholar
• Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463–5472.
   PubMed Web of Science ®Google Scholar
• Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, et al. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol 2001;29:322–329.
   PubMed Web of Science ®Google Scholar
• Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905–3914.
   PubMed Web of Science ®Google Scholar
• Agliano A, Martin-Padura I, Mancuso P, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/SCID-related strains. Int J Cancer 2008;123:2222–2227.
   PubMed Web of Science ®Google Scholar
• Ackler S, Mitten MJ, Chen J, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol 2012;167:881–891.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Stejskal A, Cooke LS, et al. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012;18:2210–2219.
   PubMed Web of Science ®Google Scholar
• Prasad A, Shrivastava A, Papadopoulos E, et al. Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma. Clin Cancer Res 2013;19:85–95.
   PubMed Web of Science ®Google Scholar
• Zullo K, Amengual JE, O’Connor OA, et al. Murine models in mantle cell lymphoma. Best Pract Res Clin Haematol 2012;25:153–163.
   PubMed Web of Science ®Google Scholar
• Bertilaccio MT, Scielzo C, Simonetti G, et al. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia 2013;27:534–540.
   PubMed Web of Science ®Google Scholar
• Sugamura K, Asao H, Kondo M, et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 1996;14:179–205.
   PubMed Web of Science ®Google Scholar
• Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175–3182.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477–6489.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180–191.
   PubMed Web of Science ®Google Scholar
• Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010;2:a001016.
   Web of Science ®Google Scholar
• Stankovic T, Skowronska A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2014;55:1227–1239.
   PubMed Web of Science ®Google Scholar
• Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. PNAS 2013;110:18250–18255.
   PubMed Web of Science ®Google Scholar
• Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leukemia Res 1999;23:127–136.
   PubMed Web of Science ®Google Scholar
• Epstein AL, Levy R, Kim H, et al. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer 1978;42:2379–2391.
   Google Scholar
• Jeon HJ, Kim CW, Yoshino T, et al. Establishment and characterization of a mantle cell lymphoma cell line. Brit J Haematol 1998;102:1323–1326.
   PubMed Web of Science ®Google Scholar
• Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994;83:1871–1875.
   PubMed Web of Science ®Google Scholar
• Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 1997;11:64–72.
   PubMed Web of Science ®Google Scholar
• Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622–629.
   PubMed Web of Science ®Google Scholar
• Vorechovsky I, Luo L, Dyer MJ, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997;17:96–99.
   PubMed Web of Science ®Google Scholar
• Williamson CT, Muzik H, Turhan AG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010;9:347–357.
   PubMed Web of Science ®Google Scholar
• Aydin S, Grabellus F, Eisele L, et al. Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model. Eur J Haematol 2011;87:10–19.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schaffner C, Winkler D, et al. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol 2000; 11(Suppl. 1):127–130.
   PubMed Web of Science ®Google Scholar
• Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002;99:6955–6960.
   PubMed Web of Science ®Google Scholar
• Ford RJ, Shen L, Lin-Lee YC, et al. Development of a murine model for blastoid variant mantle-cell lymphoma. Blood 2007;109: 4899–4906.
   PubMed Web of Science ®Google Scholar
• Attianese GM, Marin V, Hoyos V, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood 2011;117:4736–4745.
   PubMed Web of Science ®Google Scholar
• Somovilla-Crespo B, Alfonso-Pérez M, Cuesta-Mateos C, et al. Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma. J Hematol Oncol 2013;6:89.
   PubMed Web of Science ®Google Scholar
• Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010;116:4578–4587.
   PubMed Web of Science ®Google Scholar
• Shirsath NP, Manohar SM, Joshi KS. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Mol Cancer 2012;11:77.
   PubMed Web of Science ®Google Scholar
• Klanova M, Soukup T, Jaksa R, et al. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab Invest 2014;94:806–817.
   PubMed Web of Science ®Google Scholar
• Cocco C, Di Carlo E, Zupo S, et al. Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia 2012;26: 1365–1374.
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Locatelli SL, Giacomini A, et al. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. PLoS One 2013;8:e61603.
   PubMed Web of Science ®Google Scholar
• Yan JS, Chen XY, Li WP, et al. Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma. Chinese J Cancer 2009;28:181–183.
   Google Scholar
• Meyer LH, Debatin KM. Diversity of human leukemia xenograft mouse models: implications for disease biology. Cancer Res 2011;71:7141–7144.
   PubMed Web of Science ®Google Scholar